Our NGS analysis of 27 SMARCA4‐deficient thoracic tumors identified frequent mutations in TP53, CDKN2A, KRAS, STK11, NF1, and PTEN, with rare actionable oncogenic driver mutations.6, 17. This evidence concerns the gene CDKN2A and neoplasm of thorax.